CenTrial Logo

Tigulixostat Shows Significant Reduction in Gout Uric Acid Levels


Clinical trial finds tigulixostat lowers uric acid in gout patients

Gout, a type of arthritis caused by high levels of uric acid in the blood, can be a painful condition that affects the joints, particularly in the feet. However, a clinical trial has shown promising results in reducing uric acid levels and managing gout symptoms with a medication called tigulixostat.

Clinical Trial

The trial, conducted at multiple medical centers, involved gout patients with high uric acid levels. It was a 12-week trial where participants were randomly assigned to receive either tigulixostat or a placebo (an inactive substance). The aim was to assess the safety and effectiveness of tigulixostat in lowering uric acid levels in these patients.


The results from the trial were encouraging. A significantly greater number of patients who took tigulixostat achieved the target uric acid level of less than 5.0 mg/dl compared to those who received the placebo. Specifically, 47.1%, 44.7%, and 62.2% of patients in the tigulixostat groups achieved this target, while only 2.9% of patients in the placebo group did.


Moreover, the trial found that tigulixostat led to a substantial reduction in uric acid levels from baseline, with reductions ranging from 38.8% to 61.8%. This reduction was observed consistently across all doses of tigulixostat tested.


One concern with treating gout is the risk of gout flares, which are sudden and severe attacks of pain, redness, and swelling in the joints. However, the trial showed that the rate of gout flares requiring additional treatment was similar between the tigulixostat groups and the placebo group, ranging from 9.4% to 13.2%.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Importantly, the medication was well-tolerated by patients, with the majority of reported adverse events being mild or moderate in severity. This indicates that tigulixostat has an acceptable safety profile for use in gout patients.



Tigulixostat has shown promising results in reducing uric acid levels in gout patients with hyperuricemia. It significantly lowered uric acid levels compared to placebo across all doses tested in the trial, with a good safety profile. These findings suggest that tigulixostat could be a valuable treatment option for individuals suffering from gout. However, further research is needed to confirm these results and assess the long-term safety and effectiveness of the medication.


This trial provides hope for improved management of gout, offering patients a potential new option to help alleviate their symptoms and improve their quality of life.


ACR, Jan-17-23

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.